Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Dec 10, 2024

31100_dirs_2024-12-09_3c6ccf6f-797b-4118-a961-c5d8935db566.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-12-05

Reporting Person: Eydelman Mikhail (SVP, GEN COUNSEL & CORP SEC)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-12-05 Common Stock G 110 Disposed 28697 Direct
2024-12-05 Common Stock M 5000 $21.41 Acquired 33697 Direct
2024-12-05 Common Stock S 1435 $90.163 Disposed 32262 Direct
2024-12-05 Common Stock S 3177 $91.912 Disposed 29085 Direct
2024-12-05 Common Stock S 388 $92.901 Disposed 28697 Direct
2024-12-09 Common Stock F 475 $92.06 Disposed 28222 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-12-05 Stock Option (right to buy) $21.41 M 5000 Disposed 2032-05-08 Common Stock (5000) Direct

Footnotes

F1: Represents a bona fide gift of the Issuer's Common Stock to a non-profit educational institution.

F2: Includes 184 shares acquired on November 15, 2024 under the Issuer's Employee Stock Purchase Plan.

F3: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $89.655 to $90.645. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.265 to $92.175. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $92.29 to $93.11. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F7: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F8: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.